|1.||Prusiner, Stanley B: 6 articles (12/2013 - 03/2003)|
|2.||Lippes, Jack: 5 articles (08/2015 - 07/2009)|
|3.||Lu, Wan-Liang: 4 articles (08/2015 - 08/2008)|
|4.||Sokal, David C: 4 articles (03/2010 - 07/2008)|
|5.||Kataoka, Yasufumi: 4 articles (05/2007 - 01/2004)|
|6.||Das, Dipon: 3 articles (11/2015 - 01/2012)|
|7.||Kundu, Chanakya Nath: 3 articles (11/2015 - 01/2012)|
|8.||Sun, Meng-Ge: 3 articles (08/2015 - 01/2012)|
|9.||Li, Xue-Tao: 3 articles (08/2015 - 08/2014)|
|10.||Shi, Ji-Feng: 3 articles (08/2015 - 01/2012)|
01/01/2001 - "Patients who have resistant infection can usually be cured by a prolonged course of treatment with a combination of a nitroimidazole with quinacrine."
01/01/2013 - "Here, we report that quinacrine was highly active against EV71, protecting cells from EV71 infection. "
09/01/2006 - "Quinacrine significantly potentiated the anti-MAC activity of PA, suggesting the usefulness of this combination in the clinical control of MAC infection."
06/01/1998 - "vivax infections, whereas 100 mg of atebrin daily controlled symptoms of P. "
11/01/1983 - "Quinacrine alone is ineffective in therapy of chronic HBV infection. "
01/01/1999 - "In the course of WWII malaria casualties dropped beyond expectation due to an improved usage of quinacrine (Atebrine) which was based on new knowledge in pharmacokinetics. "
04/01/1951 - "[On the virulence of malaria in Greece, and the efficacy of various forms of atabrine therapy]."
11/01/1946 - "Studies on atabrine suppression of malaria; an evaluation of atabrine suppression in the field."
10/01/1945 - "Psychosis following administration of quinacrine hydrochloride for malaria; neuropsychiatric study of a case."
03/01/2015 - "Quinacrine is a relatively non-toxic drug, once given almost exclusively for malaria. "
05/10/2011 - "Quinacrine, a drug with antimalarial and anticancer activities that inhibits NF-κB and activates p53, has progressed into phase II clinical trials in cancer. "
03/01/2010 - "We feel the totality of the information provided herein dictates that the doses (70/70, 70/250 and 70/350 mg/kg quinacrine) causing uterine tumors in their study clearly exceeded the maximum tolerated dose (MTD) typically administered in chronic cancer studies. "
10/01/1955 - "Studies on the administration of quinacrine to tumor-bearing mice."
04/01/2015 - "A rat carcinogenicity bioassay (CaBio) of quinacrine was reanalyzed to investigate its mode of tumor induction. "
04/01/2015 - "A critical examination of the mode of action of quinacrine in the reproductive tract in a 2-year rat cancer bioassay and its implications for human clinical use."
|4.||Prion Diseases (Transmissible Spongiform Encephalopathies)
11/02/2006 - "The most potent target compound 2a revealed an EC(50) value of 20 nM determined with a cell model of prion disease, thus substantially improving the antiprion efficacy of quinacrine."
11/29/2004 - "In a cell-based assay, quinacrine inhibits the conversion of normal host prion protein (PrPC) to PrPSc at a half-maximal concentration of 300 nM. While these data suggest that quinacrine may be beneficial in the treatment of prion disease, its penetration into brain tissue has not been extensively studied. "
11/29/2004 - "The documented extensive brain tissue penetration is encouraging suggesting quinacrine might be useful in the treatment of prion disease. "
11/29/2004 - "If quinacrine penetrates brain tissue in concentrations exceeding that demonstrated for in vitro inhibition of PrPSc, it may be useful in the treatment of prion disease. "
04/01/2009 - "Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial."
03/01/1958 - "[Therapy of lambliasis; 52 cases effectively treated with combined mepacrine & rodoprequine]."
01/01/2012 - "The authors report the case of a 20-year-old man who presented with a de novo episode of hypomania subsequent to the initiation of quinacrine for treatment resistant giardiasis. "
12/01/1999 - "Re: Letter on quinacrine for treatment of Giardiasis--J Travel Med 1998;5:228."
12/01/1998 - "Quinacrine for treatment of giardiasis."
09/21/1991 - "[Combined oral and endoscopic mepacrine therapy in therapy-resistant symptomatic giardiasis]."
|4.||Antimalarials (Antimalarial Agents)
|6.||4- ((4- Fluoro- 2- methyl- 1H- indol- 5- yl)oxy)- 6- methoxy- 7- (3- (pyrrolidin- 1- yl)propoxy)quinazoline (AZD2171)
|1.||Drug Therapy (Chemotherapy)
|4.||Reproductive Sterilization (Female Sterilization)